PRA Health Sciences, Inc. (NASDAQ:PRAH) – Equities researchers at Jefferies Group raised their Q4 2017 earnings estimates for shares of PRA Health Sciences in a research report issued to clients and investors on Monday. Jefferies Group analyst D. Windley now anticipates that the medical research company will earn $0.91 per share for the quarter, up from their previous forecast of $0.89. Jefferies Group has a “Buy” rating and a $92.00 price target on the stock.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.10). The business had revenue of $457.90 million during the quarter, compared to analysts’ expectations of $447.79 million. PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. ILLEGAL ACTIVITY NOTICE: “Jefferies Group Weighs in on PRA Health Sciences, Inc.’s Q4 2017 Earnings (PRAH)” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/11/jefferies-group-weighs-in-on-pra-health-sciences-inc-s-q4-2017-earnings-prah.html.

PRAH has been the subject of a number of other research reports. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. Citigroup Inc. reaffirmed a “buy” rating and set a $93.00 price target (up previously from $90.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Bank of America Corporation started coverage on PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 price target for the company. Mizuho started coverage on PRA Health Sciences in a research report on Thursday, September 21st. They set a “buy” rating and a $82.00 price target for the company. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $88.00 price target on shares of PRA Health Sciences in a research report on Monday. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $84.78.

Shares of PRA Health Sciences (PRAH) opened at 81.09 on Wednesday. PRA Health Sciences has a 52-week low of $50.87 and a 52-week high of $82.00. The company’s 50-day moving average price is $76.65 and its 200-day moving average price is $72.51. The stock has a market cap of $5.08 billion, a PE ratio of 52.35 and a beta of 0.42.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in PRA Health Sciences by 144.0% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock worth $115,000 after buying an additional 906 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in PRA Health Sciences by 232.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock worth $121,000 after buying an additional 1,289 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in PRA Health Sciences in the 1st quarter worth about $136,000. Finally, Teacher Retirement System of Texas acquired a new stake in PRA Health Sciences in the 1st quarter worth about $208,000. Institutional investors own 98.37% of the company’s stock.

In related news, CEO Colin Shannon sold 400,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Linda Baddour sold 100,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $7,485,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,000,000 shares of company stock valued at $748,500,000. 2.10% of the stock is owned by company insiders.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.